




OFFICIAL PUBLICATION OF
THE MINISTRY OF HEALTH,
BRUNEI DARUSSALAM

Brunei International Medical Journal

Volume 16

14 July 2020 (22 Zulkaedah 1441H)



Brunei Int Med J. 2020;16:90-91

Brunei International Medical Journal (BIMJ)

Official Publication of the Ministry of Health, Brunei Darussalam

EDITORIAL BOARD

Editor-in-Chief	William Chee Fui CHONG
Sub-Editors	Vui Heng CHONG Ketan PANDE
Editorial Board Members	Muhd Syafiq ABDULLAH Alice Moi Ling YONG Ahmad Yazid ABDUL WAHAB Jackson Chee Seng TAN Pemasiri Upali TELISINGHE Roselina YAAKUB Pengiran Khairol Asmee PENGIRAN SABTU Dayangku Siti Nur Ashikin PENGIRAN TENGAH

INTERNATIONAL EDITORIAL BOARD MEMBERS

Lawrence HO Khek Yu (Singapore)	Surinderpal S BIRRING (United Kingdom)
Emily Felicia Jan Ee SHEN (Singapore)	Leslie GOH (United Kingdom)
John YAP (United Kingdom)	Chuen Neng LEE (Singapore)
Christopher HAYWARD (Australia)	Jimmy SO (Singapore)
Jose F LAPENA (Philippines)	Simon Peter FROSTICK (United Kingdom)
Dipo OLABUMUYI	Nazar LUQMAN

Advisor

Wilfred PEH (Singapore)

Past Editors

Nagamuttu RAVINDRANATHAN
Kenneth Yuh Yen KOK

Proof reader

John WOLSTENHOLME (CfBT Brunei Darussalam)

Aim and Scope of Brunei International Medical Journal

The Brunei International Medical Journal (BIMJ) is a six monthly peer reviewed official publication of the Ministry of Health under the auspices of the Clinical Research Unit, Ministry of Health, Brunei Darussalam.

The BIMJ publishes articles ranging from original research papers, review articles, medical practice papers, special reports, audits, case reports, images of interest, education and technical/innovation papers, editorials, commentaries and letters to the Editor. Topics of interest include all subjects that relate to clinical practice and research in all branches of medicine, basic and clinical including topics related to allied health care fields. The BIMJ welcomes manuscripts from contributors, but usually solicits reviews articles and special reports. Proposals for review papers can be sent to the Managing Editor directly. Please refer to the contact information of the Editorial Office.

Instruction to authors

Manuscript submissions

All manuscripts should be sent to the Managing Editor, BIMJ, Ministry of Health, Brunei Darussalam; e-mail: editor-in-chief@bimjonline.com. Subsequent correspondence between the BIMJ and authors will, as far as possible via should be conducted via email quoting the reference number.

Conditions

Submission of an article for consideration for publication implies the transfer of the copyright from the authors to the BIMJ upon acceptance. The final decision of acceptance rests with the Editor-in-Chief. All accepted papers become the permanent property of the BIMJ and may not be published elsewhere without written permission from the BIMJ.

Ethics

Ethical considerations will be taken into account in the assessment of papers that have experimental investigations of human or animal subjects. Authors should state clearly in the Materials and Methods section of the manuscript that institutional review board has approved the project. Those investigators without such review boards should ensure that the principles outlined in the Declaration of Helsinki have been followed.

Manuscript categories

Original articles

These include controlled trials, interventional studies, studies of screening and diagnostic tests, outcome studies, cost-effectiveness analyses, and large-scale epidemiological studies. Manuscript should include the following; introduction, materials and methods, results and conclusion. The objective should be stated clearly in the introduction. The text should not exceed 2500 words and references not more than 30.

Review articles

These are, in general, invited papers, but unsolicited reviews, if of good quality, may be considered. Reviews are systematic critical assessments of

literature and data sources pertaining to clinical topics, emphasising factors such as cause, diagnosis, prognosis, therapy, or prevention. Reviews should be made relevant to our local setting and preferably supported by local data. The text should not exceed 3000 words and references not more than 40.

Special Reports

This section usually consist of invited reports that have significant impact on healthcare practice and usually cover disease outbreaks, management guidelines or policy statement paper.

Audits

Audits of relevant topics generally follow the same format as original article and the text should not exceed 1,500 words and references not more than 20.

Case reports

Case reports should highlight interesting rare cases or provide good learning points. The text should not exceed 1000 words; the number of tables, figures, or both should not be more than two, and references should not be more than 15.

Education section

This section includes papers (i.e. how to interpret ECG or chest radiography) with particular aim of broadening knowledge or serve as revision materials. Papers will usually be invited but well written paper on relevant topics may be accepted. The text should not exceed 1500 words and should include not more than 15 figures illustration and references should not be more than 15.

Images of interest

These are papers presenting unique clinical encounters that are illustrated by photographs, radiographs, or other figures. Image of interest should include a brief description of the case and discussion with educational aspects. Alternatively, a mini quiz can be presented and answers will be posted in a different section of the publication. A maximum of

three relevant references should be included. Only images of high quality (at least 300dpi) will be acceptable.

Technical innovations

This section include papers looking at novel or new techniques that have been developed or introduced to the local setting. The text should not exceed 1000 words and should include not more than 10 figures illustration and references should not be more than 10.

Letters to the Editor

Letters discussing a recent article published in the BIMJ are welcome and should be sent to the Editorial Office by e-mail. The text should not exceed 250 words; have no more than one figure or table, and five references.

Criteria for manuscripts

Manuscripts submitted to the BIMJ should meet the following criteria: the content is original; the writing is clear; the study methods are appropriate; the data are valid; the conclusions are reasonable and supported by the data; the information is important; and the topic has general medical interest. Manuscripts will be accepted only if both their contents and style meet the standards required by the BIMJ.

Authorship information

Designate one corresponding author and provide a complete address, telephone and fax numbers, and e-mail address. The number of authors of each paper should not be more than twelve; a greater number requires justification. Authors may add a publishable footnote explaining order of authorship.

Group authorship

If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship described in the following paragraphs. One or more authors may take responsibility 'for' a group, in which case the other group members are not authors, but may be listed in an acknowledgement.

Authorship requirement

When the BIMJ accepts a paper for publication, authors will be asked to sign statements on (1) financial disclosure, (2) conflict of interest and (3) copyright transfer. The correspondence author may sign on behalf of co-authors.

Authorship criteria and responsibility

All authors must meet the following criteria: to have participated sufficiently in the work to take public responsibility for the content; to have made substantial contributions to the conception and de-

sign, and the analysis and interpretation of the data (where applicable); to have made substantial contributions to the writing or revision of the manuscript; and to have reviewed the final version of the submitted manuscript and approved it for publication. Authors will be asked to certify that their contribution represents valid work and that neither the manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, except as described in an attachment. If requested, authors shall provide the data on which the manuscript is based for examination by the editors or their assignees.

Financial disclosure or conflict of interest

Any affiliation with or involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in the manuscript should be disclosed in an attachment. Any financial or material support should be identified in the manuscript.

Copyright transfer

In consideration of the action of the BIMJ in reviewing and editing a submission, the author/s will transfer, assign, or otherwise convey all copyright ownership to the Clinical Research Unit, RIPAS Hospital, Ministry of Health in the event that such work is published by the BIMJ.

Acknowledgements

Only persons who have made substantial contributions but who do not fulfill the authorship criteria should be acknowledged.

Accepted manuscripts

Authors will be informed of acceptances and accepted manuscripts will be sent for copyediting. During copyediting, there may be some changes made to accommodate the style of journal format. Attempts will be made to ensure that the overall meaning of the texts are not altered. Authors will be informed by email of the estimated time of publication. Authors may be requested to provide raw data, especially those presented in graph such as bar charts or figures so that presentations can be constructed following the format and style of the journal. Proofs will be sent to authors to check for any mistakes made during copyediting. Authors are usually given 72 hours to return the proof. No response will be taken as no further corrections required. Corrections should be kept to a minimum. Otherwise, it may cause delay in publication.

Offprint

Contributors will not be given any offprint of their published articles. Contributors can obtain an electronic reprint from the journal website.

DISCLAIMER

All articles published, including editorials and letters, represent the opinion of the contributors and do not reflect the official view or policy of the Clinical Research Unit, the Ministry of Health or the institutions with which the contributors are affiliated to unless this is clearly stated. The appearance of advertisement does not necessarily constitute endorsement by the Clinical Research Unit or Ministry of Health, Brunei Darussalam. Furthermore, the publisher cannot accept responsibility for the correctness or accuracy of the advertisers' text and/or claim or any opinion expressed.

Abdur Rahman **RUBEL**, Babu Ivan MANI, May Thu **HLA AYE**, Waqas Ahmed **CHAUHDARY**, Aieman **BASHIR**, Zar Ni **SOE**, Nasir **JAVED**, Shah Muhammad Alam **SHARIF**, Chee Fui **CHONG**, Vui Heng **CHONG**




Figure 1

A 48-year-old lady with a history hypertension, iron deficiency anemia, ex-smoker and family history of coronary artery disease presented with sudden onset of epigastric pain. This was associated with radiation to the back and left shoulder, numbness along the left upper limb, giddiness and nausea. 12 leads ECG showed ST segment sagging in the inferior leads (III and aVF) and lead V3 (Figure 1a). Troponin I initially measured was mildly elevated at 32ng/L (normal range <30ng/L) but later increased to 836ng/L consistent with non-ST segment elevation myocardial infarction (NSTEMI). She was given aspirin, plavix and statin. Urgent coronary angiography was arranged (Figure 1b and 1c) which showed a smooth narrowed long segment of the mid left anterior descending artery (LAD).

What is the abnormality depicted in the coronary angiogram and what is the diagnosis?

Answer: refer to page 91

Correspondence author: Dr. Abdur Rahman RUBEL, Department of Medicine, PMMPHAMB Hospital, Jalan Sungai Basong, Tutong, Brunei Darussalam.
E mail: mdarubel130@gmail.com

DISCLOSURE: All authors have no competing or conflicting interest in the production of this manuscript. All authors have not received any funding for the production of this manuscript and consent has been obtained from patient's parents/guardians to publish these images.

(Refer to page 90)

ANSWER: MYOCARDIAL BRIDGING OF MID LAD ARTERY RESULTING IN NSTEMI.

The coronary angiogram showed a narrowed (black and white arrows) segment of the mid left anterior descending (LAD) that is located a slightly lower plane due to myocardial bridging. The tunneling of the artery located at a lower plane is more obvious (black and white arrow) in Panel B. Black arrow in Figure A indicate the metal component of the ECG lead.

[Myocardial bridge](#) is a congenital abnormality where a segment of a major epicardial coronary artery runs intra-murally (tunneled artery) through the myocardium as depicted by angiogram in Figure 1c.^{1,2} The incidence of myocardial bridging from an autopsy study of 90 hearts from patients who did not have a history of established heart disease or cardiac-related death was about 55% and the majority exclusively involved the Left anterior descending artery (LAD) in 70%, 40% involved the left circumflex artery and only 36% involved the right coronary artery.¹

Intracoronary flow studies using quantitative coronary angiography and intracoronary Doppler imaging showed that intracoronary haemodynamic flow was characterized by phasic systolic compression with a localized peak pressure, persistent decrease in diastolic coronary diameter with a delay relaxation, an increase in blood flow velocities

and retrograde flow, and a reduced flow reserve.¹ These haemodynamic flow abnormalities which are worsen with tachycardia, can lead to endothelial dysfunction secondary to turbulent blood flow with subsequent plaque formation just proximal and distal to the myocardial bridge.^{1,2}

Patients with myocardial bridging, although present at birth, do not develop symptoms until after the third decade.¹ In 40% of patients, symptoms of angina can be brought on after administration of nitroglycerin or beta agonists.¹ Reported complications include angina pectoris, myocardial infarction, life threatening arrhythmias, and even sudden cardiac death.¹

Diagnosis of myocardial bridging are usually confirmed by coronary angiogram, although non-invasive modality like multiple-slice computed tomography (MSCT) has also been used.² Intravascular ultrasound has also been utilized to provide physiological flow data and imaging of myocardial bridging coronary segment, which is typically characterized by the "[half-moon sign](#)".²

In most cases, myocardial bridge is non-significant and does not require any intervention. Treatment is mostly medical (first choice beta blockers).³ Use of nitrates may worsen the symptoms and should be avoided. Percutaneous coronary intervention with intracoronary stents or surgical myotomy are alternative options should medical therapy failed.³

REFERENCES

- 1: Lee MS, Chen CH. [Myocardial Bridging: An Up-to-Date Review](#). J Invasive Cardiol. 2015; 27:521-8. [Accessed on 12 July 2020].
- 2: Corban MT, Hung OY, Eshtehardi P, Rasoul-Arzrumly E, McDaniel M, Mekonnen G, et al. [Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies](#). J Am Coll Cardiol. 2014; 63:2346-55. [Accessed on 12 July 2020].
- 3: Alegria JR, Herrmann J, Holmes DR Jr, Lerman A, Rihal CS. [Myocardial bridging](#). Eur Heart J. 2005;26:1159-68. [Accessed on 12 July 2020].